MedTrace Logo

Genetic Testing to Understand and Address Renal Disease Disparities Across the United States Pharmacogenetic Substudy

NCT06748040 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1874

Last updated 2025-06-17

Study results available
· View outcomes & findings →

Summary

This is a substudy of GUARDD-US (Genetic testing to Understand and Address Renal Disease Disparities across the United States, NCT04191824). Its primary purpose is to determine the effect of knowledge of genetic test results that predict efficacy of various antihypertensive medications on change in SBP (systolic blood pressure) from baseline to 3 months in APOL1 (apolipoprotein L1) negative individuals at participating sites.

Conditions

Interventions

OTHER

Timing of return of results

Participants will be randomized to immediate versus delayed return of PGx results.

Sponsors & Collaborators

Principal Investigators

  • Hrishikesh Chakraborty, DrPH · Duke University

  • Carol Horowitz, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-10
Primary Completion
2024-04-09
Completion
2024-05-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06748040 on ClinicalTrials.gov